Skip to main content
Premium Trial:

Request an Annual Quote

Covance, ISB Partner on Brain Tumor Biology Research

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Contract research organization Covance today announced a collaboration between its genomics laboratory in Seattle and the Institute for Systems Biology to further research into brain tumor biology.

Specifically, Covance's expertise in genomics assays and ISB's expertise in complex genomic networks will be leveraged to unravel the regulation of gene expression in glioblastoma multiforme.

The partners will perform next-generation sequencing to generate datasets, which will be used by researchers to investigate tumor heterogeneity and to find targets for patient stratification and/or therapeutics, Covance said. The goal is to provide a high-quality map of gene expression and RNA structure to enable research into brain tumor biology, it added.

Financial and other terms of the deal were not disclosed.

"The ability to resolve complex regulatory networks requires reproducible, high-quality data," Lee Hood, president of ISB, said in a statement. "We know Covance's experience in genomics and next-generation sequencing will give us an unprecedented level of high-quality data."

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.